Emergency Use Authorization

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

Retrieved on: 
Sunday, January 8, 2023
Emergency Use Authorization, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Party, Infection, COVID-19, Partner, Novartis, EUA, Letter, DLL3, Molecular Partners, Definitive, Intellectual property, FDA, Therapy, Conference, DARPin, Pharmaceutical industry, CONCORD

Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.

Key Points: 
  • Expression of DLL3 is low in healthy tissue but significantly increased in certain tumor types, providing an opportunity for selective targeting.
  • *
    Molecular Partners and Novartis signed a non-binding letter of intent to negotiate a Research Framework Agreement with a primary focus on emerging infectious global health threats.
  • Patrick Amstutz, CEO of Molecular Partners, will present at the 41st Annual JP Morgan Healthcare Conference on Wednesday, January 11 at 10:30 AM ET (4:30 PM CET).
  • A webcast will be accessible on the Molecular Partners website, under the Events tab .

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIG

Retrieved on: 
Tuesday, January 3, 2023
Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, District court, News, Peginterferon-alfa, Patient, EUA, Court, Investment, FDA, Therapy, The Legal 500, Labour government, Advertising, Eiger, Pharmaceutical industry, Renewable energy, Security (finance)

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.
  • Eiger is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test

Retrieved on: 
Tuesday, January 3, 2023
POC, Infection, Emergency Use Authorization, Smartphone, COVID-19, Pharmacy, Virus, Lucira, OTC, FDA, COVID, Pharmaceutical industry

EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.

Key Points: 
  • EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test.
  • Lucira’s test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in November 2022.
  • In seeking OTC authorization, Lucira intends to make the test broadly available to consumers both online as well as in pharmacies.
  • Lucira worked closely with the FDA to complete additional testing to demonstrate that the COVID & Flu test could be used by consumers at home.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline – EIGR

Retrieved on: 
Sunday, January 1, 2023
Food, Emergency Use Authorization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pomerantz, COVID-19, District court, Peginterferon-alfa, News, Person, Patient, EUA, Court, Ext, FDA, Therapy, Complaint, Eiger, SEC Rule 10b-5, Pharmaceutical industry, Renewable energy

NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers.

Key Points: 
  • NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIG

Retrieved on: 
Tuesday, December 27, 2022
Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, District court, News, Peginterferon-alfa, Patient, EUA, Court, Investment, FDA, Therapy, The Legal 500, Labour government, Advertising, Eiger, Pharmaceutical industry, Renewable energy, Security (finance)

NEW YORK, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.
  • Eiger is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline – EIGR

Retrieved on: 
Saturday, December 24, 2022
Food, Emergency Use Authorization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pomerantz, COVID-19, District court, Peginterferon-alfa, News, Person, Patient, EUA, Court, Ext, FDA, Therapy, Complaint, Eiger, SEC Rule 10b-5, Pharmaceutical industry, Renewable energy

NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers.

Key Points: 
  • NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIG

Retrieved on: 
Tuesday, December 20, 2022
Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, District court, News, Peginterferon-alfa, Patient, EUA, Court, Investment, FDA, Therapy, The Legal 500, Labour government, Advertising, Eiger, Pharmaceutical industry, Renewable energy, Security (finance)

NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.
  • Eiger is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

Retrieved on: 
Friday, January 6, 2023
Class Action Lawsuit, Professional Services, Legal, Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Peginterferon-alfa, News, Suite, EUA, Court, Defendant, FDA, Eiger, Law, Pharmaceutical industry

On September 6, 2022, Eiger provided an update on the status of its planned request for EUA, disclosing that “[f]ollowing a cooperative and extensive pre-EUA information exchange with [the] FDA .

Key Points: 
  • On September 6, 2022, Eiger provided an update on the status of its planned request for EUA, disclosing that “[f]ollowing a cooperative and extensive pre-EUA information exchange with [the] FDA .
  • If you purchased or otherwise acquired Eiger securities during the Class Period, you may move the Court no later than January 9, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

Retrieved on: 
Monday, December 19, 2022
GPM, Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Peginterferon-alfa, News, Suite, EUA, Court, Defendant, Investment, FDA, Eiger, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Eiger securities during the Class Period, you may move the Court no later than January 9, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Tuesday, January 3, 2023
IgA nephropathy, Patient, Immunoglobulin A, Social conditions in Honduras, Partnership, RNA transfection, Growth, CMC, COVID-19, Mount Everest, HKEX, Eravacycline, Ulcerative colitis, News, Degenerative disease, Prevalence, Infection, NDA, Cancer, Vaccine, Emergency Use Authorization, Kidney, Pharmaceutical industry

SHANGHAI, Jan. 3, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its strategic plans for the next two years and beyond as the Company progresses to becoming a fully-integrated biopharmaceutical company with expertise and capabilities across the full biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization . The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.

Key Points: 
  • The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.
  • The potential approval and launch of Nefecon, the Company's lead renal portfolio product candidate, is expected in China in the second half of 2023.
  • Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets.
  • Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development.